The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. حسب Gui Araujo (22170819)

"…Parameter values: interaction strengths were drawn from a half-normal distribution of zero mean and a standard deviation of 0.2, and strength for consumers was made no larger than the strength for resources. …"

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

A prepubertal CD decreases hepatic lipid accumulation in adulthood despite a chronic HFD in Sprague-Dawley male rats. حسب Ana Aguilar-Lozano (20614619)

A prepubertal CD decreases plasma leptin and cholesterol concentrations in adulthood despite a chronic HFD in Sprague-Dawley male rats. حسب Ana Aguilar-Lozano (20614619)

Naringenin decreases total cell viability. حسب Lauren A. Eanes (20995499)

PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. حسب Katherine Schubert (5452712)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Participant demographics. * P-values were determined using Fisher-Freeman-Halton test when contingency tables are larger than 2 × 2. حسب Elie Mulhem (22537863)

الموضوعات:

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. حسب Peiqi Yin (6533747)

Study selection criteria. حسب Filip Stanicic (17808254)

الموضوعات:

PICOS criteria for the SLR. حسب Filip Stanicic (17808254)

الموضوعات:

PRISMA flow chart. حسب Filip Stanicic (17808254)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

Cephalometric measurement points. حسب Lijuan Liu (136685)

الموضوعات:

Selection frequencies plotted in decreasing order. حسب Hannah P. Rowe (7830599)

HFD decreases intermediate-term memory. حسب Tong Yue (6033305)

"…<p>(A) The survival rate of 10d <i>Canton-S</i> fed with ND or HFD was observed for 7 days. …"